{"id":2305,"date":"2010-08-03T18:59:35","date_gmt":"2010-08-03T22:59:35","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=2305"},"modified":"2011-07-19T17:44:54","modified_gmt":"2011-07-19T21:44:54","slug":"vitamin-b-trial-finds-no-clinically-significant-benefit","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/08\/03\/vitamin-b-trial-finds-no-clinically-significant-benefit\/","title":{"rendered":"Vitamin B Trial Finds No Clinically Significant Benefit"},"content":{"rendered":"<p>The VITATOPS (The VITAmins TO Prevent Stroke) Trial randomized 8164 patients with recent stroke or TIA to either placebo or B vitamins. After a median followup of 3.4 years, the primary endpoint\u00a0\u2014 the combined incidence of stroke, MI, or vascular death\u00a0\u2014 occurred in 616 patients in the B vitamin group and 678 in the placebo group, for an absolute risk reduction of 1.56%. The modest 9% reduction in relative risk, with a 95% confidence interval ranging from 0% to 18%, led the authors to write in their <a href=\"http:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422%2810%2970187-3\/abstract\">report in <em>Lancet Neurology<\/em><\/a> that &#8220;our findings do not definitively confirm that supplementation with B vitamins has a clinically significant beneficial effect on major vascular events.&#8221;<\/p>\n<p><a href=\"http:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422%2810%2970188-5\/fulltext\">In an accompanying &#8220;Reflection and Reaction,&#8221;<\/a> Peter Sandercock writes that the results are not &#8220;sufficiently robust&#8221; enough to support usage of vitamin B supplements, however, one cannot rule out the possibility that &#8220;B vitamins could still be potentially worthwhile.&#8221; He notes, however, that it may be difficult if not impossible &#8220;in the present regulatory environment&#8221; to successfully mount a clinical trial for this sort of non-commercial intervention.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The VITATOPS (The VITAmins TO Prevent Stroke) Trial randomized 8164 patients with recent stroke or TIA to either placebo or B vitamins. After a median followup of 3.4 years, the primary endpoint\u00a0\u2014 the combined incidence of stroke, MI, or vascular death\u00a0\u2014 occurred in 616 patients in the B vitamin group and 678 in the placebo [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[253,254,252],"class_list":["post-2305","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-stroke","tag-supplements","tag-vitamin-b"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/2305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=2305"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/2305\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=2305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=2305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=2305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}